Addition of low-dose decitabine to bortezomib and dexamethasone as second-line therapy in multiple myeloma

Br J Haematol. 2020 Jun;189(6):e258-e262. doi: 10.1111/bjh.16686. Epub 2020 Apr 28.

Authors

Ning Li¹, Lina Liu², Pu Xiang², Lijie Liang², Juan Wang², Yaomei Wang², Suxia Luo¹, Yongping Song², Baijun Fang²

Affiliations

¹ Department of Oncology, Henan Cancer Hospital, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.
² Department of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.

PMID: 32346851
DOI: 10.1111/bjh.16686

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bortezomib / administration & dosage
Bortezomib / adverse effects
Decitabine / administration & dosage
Decitabine / adverse effects
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma / blood
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality*
Survival Rate

Substances

Bortezomib
Decitabine
Dexamethasone

Grants and funding